KALA BIO (KALA) Stock Analysis
NASDAQHealthcareBiotechnology
What KALA BIO does
Kala Bio, Inc. functions as a biopharmaceutical company dedicated to the creation and commercialization of new therapeutic solutions. The core of their strategy involves utilizing proprietary nanoparticle technology, specifically mucus penetrating particles (MPPs). Initially, their focus for these treatments is directed towards ophthalmic diseases. The company was established in 2009 by co-founders Justin Hanes, Robert S. Langer, and Colin R. Gardner, and its headquarters are located in Arlington, Massachusetts.
Key metrics
ETFs linked to KALA
Broad-market and Healthcare sector ETFs an investor holding KALA BIO is often also exposed to. Open an ETF page to see its actual top holdings.
PortView Portfolio Insights
PortView analyzes how KALA fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.
Analyze KALA in PortView →Similar companies
Frequently asked questions
- What is the ticker symbol for KALA BIO?
- KALA BIO trades under the ticker KALA on NASDAQ.
- Which exchange is KALA listed on?
- KALA is listed on NASDAQ.
- What sector does KALA BIO operate in?
- KALA BIO is classified in the Healthcare sector (Biotechnology industry).
- How can PortView help analyze KALA in a portfolio?
- PortView shows KALA's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.
The information provided by PortView is for informational and educational purposes only and does not constitute investment advice. Market data may be delayed. Past performance does not guarantee future results.